You are here

Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI131823-02
Agency Tracking Number: R42AI131823
Amount: $1,501,157.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-04-18
Award End Date (Contract End Date): 2021-03-31
Small Business Information
935 E EAGLEWOOD DR
North Salt Lake, UT 84054-3302
United States
DUNS: 080197308
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HUA WU
 (605) 679-6985
 hwu@sabbiotherapeutics.com
Business Contact
 PETER BOEREMA
Phone: (605) 231-8058
Email: pboerema@sabbiotherapeutics.com
Research Institution
 UTAH STATE UNIVERSITY
 
1415 Old main Hill Old Main Room 64
LOGAN, UT 84322-1415
United States

 Nonprofit college or university
Abstract

Project Summary/Abstract
The ultimate goal of this phase II STTR proposal is to expand the capabilities of SABandapos;s diversitAbâ„¢ platform by
continuing advanced development of Transchromosomic goats (TcGs). This will be accomplished by producing
male and female goat endogenous immunoglobulin gene knockout cell lines that contain SAB Capraandapos;s human
artificial chromosome (HAC) which encodes the entire repertoire of the germline human antibody genes thereby
greatly improving the production efficiency of fully human antibodies in TcGs. To further advance the TcG
platform towards commercial production of therapeutic and diagnostic antibody products, optimization of the
antibody purification process, development of quality control assays, and further development of a purified TcG-
derived pandemic influenza antibody product targeting H7N9 by completing in-vitro and in-vivo evaluation is also
proposed.
To accomplish these goals, endogenous immunoglobulin gene knockouts will be facilitated utilizing the
CRISPR/Cas9 system in domestic Nubian/Boar goat fetal fibroblast (GFF) cells, and transfer of the SAB-
designed HAC into the knockout cells will be accomplished by microcell mediated chromosome transfer (MMCT).
HAC-containing knockout GFF cells will be used to produce embryos by somatic cell nuclear transfer (SCNT).
After gestation and birth of multiple TcGs, molecular characterization will be completed, presence of the
knockouts and HAC will be confirmed, and human IgG production will be confirmed and evaluated. Two of these
TcGs will then be hyperimmunized with a plasmid DNA vaccine targeting H7N9. Plasma will be collected from
the hyperimmunized TcGs, and anti-H7N9 fully human IgG will be purified from the TcG plasma. The in-vitro
potency and in-vivo efficacy of the purified TcG-derived anti-H7N9 human IgG product will then be evaluated.
Optimization of established purification procedures will be undertaken to ensure efficient and effective purification
of TcG-derived human IgG from plasma, and development of quality control assays to evaluate product identity,
purity, and potency will be completed.
SABandapos;s diversitAbâ„¢ platform for human antibody production is currently utilized in transchromosomic bovines
against a wide range of antigens including viruses, bacteria, oncology targets, recombinant proteins, and DNA
vaccines. This proven technology has the advantages of scalability, simplicity, and broad applicability. The
addition of TcGs to the platform allows for simpler and cheaper rapid-response production of small volume
targeted products as well as diagnostic reagents for serological testing of emerging infectious diseases.Project Narrative
The research proposed in this application seeks to expand the capabilities of SABandapos;s diversitAbâ„¢ platform by
continuing advanced development of Transchromosomic goats (TcGs) that express human polyclonal antibodies
for use as targeted immunotherapies and/or diagnostic reagents for serological testing. Immunotherapy products
derived from TcGs will combine the beneficial effects of current animal derived antibody products with improved
efficacy and safety while eliminating the risk of anaphylaxis and serum sickness associated with xenobiotic IgG
administration. A TcG-derived anti-H7N9 fully human IgG product will also be developed through this proposal,
potentially addressing the global need for highly effective therapeutics against avian lineage influenza virus
infections in humans.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government